HUTCHMED Initiates the P-I Study of HMPL-415 for Advanced Malignant Solid Tumors in China
Shots:
- The first patient has been dosed in the P-I study evaluating the safety, tolerability, PK, and preliminary efficacy profile of HMPL-415 as monotx. in patients with advanced malignant solid tumors
- Additionally, ~80 patients are expected to be enrolled in the study incl. patients as part of the dose escalation stage, and further patients at RP2D
- HMPL-415, a novel, highly potent, and selective allosteric inhibitor that targets protein tyrosine phosphatase-2 containing SHP2. This protein modulates various cell signaling events that control cell migration, differentiation, oncogenic transformation, transcription, cell growth, and metabolism
Ref: Globenewswire | Image: HUTCHMED
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
